Nisa Investment Advisors LLC lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 18.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 199,018 shares of the conglomerate's stock after selling 46,521 shares during the period. Nisa Investment Advisors LLC's holdings in Danaher were worth $40,862,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Bank Pictet & Cie Europe AG increased its holdings in shares of Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after acquiring an additional 35,730 shares during the last quarter. Proficio Capital Partners LLC increased its stake in Danaher by 28.0% in the fourth quarter. Proficio Capital Partners LLC now owns 2,566 shares of the conglomerate's stock valued at $589,000 after purchasing an additional 562 shares during the last quarter. Sound View Wealth Advisors Group LLC raised its holdings in Danaher by 3.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after purchasing an additional 52 shares in the last quarter. Moran Wealth Management LLC lifted its position in shares of Danaher by 2.5% during the 4th quarter. Moran Wealth Management LLC now owns 2,413 shares of the conglomerate's stock worth $554,000 after buying an additional 58 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Danaher by 4.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 102,311 shares of the conglomerate's stock valued at $23,486,000 after buying an additional 4,287 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Stock Down 0.3%
NYSE DHR traded down $0.71 on Friday, hitting $204.80. 2,369,010 shares of the stock traded hands, compared to its average volume of 3,501,539. The company has a market capitalization of $146.57 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The stock has a 50-day moving average of $195.94 and a 200 day moving average of $206.65. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. As a group, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.
Danaher Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio is presently 24.85%.
Analyst Ratings Changes
Several equities analysts have issued reports on DHR shares. Robert W. Baird dropped their target price on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Wells Fargo & Company decreased their price objective on Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. Stifel Nicolaus raised shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price for the company in a research note on Friday, March 14th. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $248.43.
Read Our Latest Report on Danaher
Insider Buying and Selling at Danaher
In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
